A Phase 3 interventional study of gilteritinib and azacitidine in Acute Myeloid Leukemia (AML) and Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, sponsored by Astellas Pharma Global Development, Inc.. Completed at 111 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute — 13 open to participants now, 15 under way, 6 of them phase 3. gilteritinib · Leukemia, Myeloid, Acute.
Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, this one is the 13th largest by enrollment, is one of 3 that started in 2016, is one of 8 in phase 3, and was the 7th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →13 of the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute are open now, in 7 countries. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 14–70
Technische Universität Dresden · Sites in Germany
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 14+
French Innovative Leukemia Organisation · Sites in France
Ages 18+
By country, each count listing its studies:
gilteritinib: first FDA approval 2018 (XOSPATA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 16 · Phase 3 10
First in 2013; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 183 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 97 across the 31 interventional studies. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Astellas Pharma Global Development, Inc., one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.
Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.
22 studies in Leukemia, Myeloid, Acute by Astellas Pharma Inc: none open now, 1 under way, none of them phase 3. Of 19 finished, 11 (58%) have results posted.
Among the 22 studies in Leukemia, Myeloid, Acute by Astellas Pharma Inc, this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2016, is one of 4 in phase 3, and was the 9th registered.
Astellas Pharma Inc’s Leukemia, Myeloid, Acute studies by the year they started, since 2006.
1 of the studies testing gilteritinib in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05024552H. Lee Moffitt Cancer Center and Research InstituteVyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML | 2027-02-15 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Astellas Pharma Inc’s 22 in Leukemia, Myeloid, Acute:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a clinical study for adult participants who were recently diagnosed with acute myeloid leukemia or AML. AML is a type of cancer. It is when bone marrow makes white blood cells that are not normal. These are called leukemia cells. Some participants with AML have a mutation, or change, in the FLT3 gene. This gene helps leukemia cells make a protein called FLT3. This protein causes the leukemia cells to grow faster.
For participants with AML who could not receive standard chemotherapy, azacitidine (also known as Vidaza®) was a current standard of care treatment option in the United States. This clinical study tested an experimental medicine called ASP2215, also known as gilteritinib. Gilteritinib worked by stopping the leukemia cells from making the FLT3 protein. This helped stop the leukemia cells from growing faster.
This study compared two different treatments. Participants were assigned to one of these two groups by chance: a medicine called azacitidine, also known as Vidaza®, or an experimental medicine gilteritinib in combination with azacitidine. There was a twice as much chance to receive both medicines combined than azacitidine alone. The clinical study may help show which treatment helps patients live longer.
Participants considered an adult according to local regulation at the time of obtaining informed consent participated in the study.
Safety Cohort Prior to initiation of the randomized trial, 15 participants were enrolled to evaluate the safety and tolerability of ASP2215 given with azacitidine therapy in the study population.
Randomized Trial Approximately 250 participants were randomized in a 2:1 ratio to receive ASP2215 plus azacitidine (Arm AC) or azacitidine only (Arm C). Participants entered the screening period up to 14 days prior to the start of treatment. Participants administered treatment over 28-day cycles.
Earlier protocol versions included a 1:1:1 randomization ratio to receive Arm A: ASP2215, Arm AC: ASP2215 + azacitidine or Arm C: azacitidine. Participants previously randomized to Arm A continued following treatment and assessments as outlined in the protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject is ineligible for intensive induction chemotherapy by meeting at least 1 of the following criteria:
Subject must meet the following criteria as indicated on the clinical laboratory tests:
Female subject is eligible to participate if female subject is not pregnant and at least one of the following conditions applies:
Exclusion Criteria:
Subject has received previous therapy for AML, with the exception of the following:
Subject has active or C or other active hepatic disorder.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 80 mg (2 tablets of 40 mg) of gilteritinib orally once daily for continuous 28-day cycles and 75 mg/m\^2 of AZA daily via subcutaneous injection or intravenous infusion for 7 days of each 28-day treatment cycle. Depending on the safety cohort data ,the decision to initiate the randomized trial at the targeted dose was made. After the end of treatment period, participants were followed up for 30- day follow up period. Participants were allowed to enter the long-term follow-up period of up to 3 years for collection of subsequent AML treatment, EQ-5D-5L, remission status and survival (cause of death and date of death). Participants in long-term follow-up who were no longer receiving treatment were followed every 3 months for survival until the implementation of the final protocol version 13.0, at which time they were discontinued from the study, as further survival data were no longer needed.
Drug: gilteritinib · Drug: azacitidine
Participants received 120 mg(3 tablets of 40 mg)of gilteritinib orally once daily for continuous 28-day cycles in combination with 75mg/m\^2 of AZA daily via subcutaneous injection or IV infusion for 7days of each 28-day treatment cycle until the participant no longer received clinical benefit from therapy in the opinion of the investigator,unacceptable toxicity occurred,or the participant met another treatment discontinuation criterion.After the end of treatment period,participants were followed up for 30-day follow up period.Participants were allowed to enter the long-term follow-up period of up to 3 years for collection of subsequent AML treatment,EQ-5D-5L,remission status and survival (cause and date of death).Participants in long-term follow-up who were no longer receiving treatment were followed every 3months for survival until the implementation of the final protocol version 13.0, at which time they were discontinued from the study,as further survival data were no longer needed.
Drug: gilteritinib
Participants received 75 mg/m\^2 of AZA daily via subcutaneous injection or intravenous infusion for 7 days of each 28-day treatment cycle until the participant no longer received clinical benefit from therapy in the opinion of the investigator, unacceptable toxicity occurred or the participant met another treatment discontinuation criterion. After the end of treatment period, participants were followed up for 30- day follow up period. Participants were allowed to enter the long-term follow-up period of up to 3 years for collection of subsequent AML treatment, EQ-5D-5L, remission status and survival (cause of death and date of death). Participants in long-term follow-up who were no longer receiving treatment were followed every 3 months for survival until the implementation of the final protocol version 13.0, at which time they were discontinued from the study, as further survival data were no longer needed.
Drug: gilteritinib · Drug: azacitidine
Participants received 120 mg (3 tablets of 40 mg) of gilteritinib orally once daily for continuous 28-day cycles until the participant no longer received clinical benefit from therapy in the opinion of the investigator, unacceptable toxicity occurred or the participant met another treatment discontinuation criterion. However, randomization to this arm was removed in protocol version 7.0. Participants previously randomized to this arm continued following treatment and assessments as outlined in the protocol.
Drug: azacitidine
Tablet, oral
Also known as: ASP2215
Subcutaneous injection or intravenous infusion
Overall Survival (OS)
OS was defined as the time from the date of randomization until the date of death from any cause. For a participant who was not known to have died by the end of study follow-up, OS was censored at the date of last contact. Kaplan-Meier (KM) estimates was used for analysis.
Time frame: From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)
Event-free Survival (EFS)
EFS: time from the date of randomization until the date of documented relapse from Complete Remission (CR), treatment failure(failing to achieve CR within 6 cycles of treatment) or death from any cause, whichever occurred first. CR: bone marrow(BM) regenerating normal hematopoietic cells, morphologically leukemia-free state, absolute neutrophil count (ANC) ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being red blood cell (RBC) and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. Relapse: reappearance of leukemic blasts \>2% in the peripheral blood/≥ 5% myeloblasts in the BM unattributable to any other cause/new/reappearance of extramedullary leukemia.
Time frame: From the date of randomization until the date of documented relapse from CR, treatment failure or death from any cause, whichever occurred first (up to 39.7 months)
Percentage of Participants With Best Response
Best response for a participant was defined as the best measured response (in the order of CR, CR with Incomplete Platelet Recovery (CRp), CR with Incomplete Hematologic Recovery (CRi), and treatment failure) from all post-baseline visits. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. CRp: achieved CR except incomplete platelet recovery (\< 100 × 10\^9/L). CRi: achieved CR except incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence not required.
Time frame: From the date of randomization until the date of death from any cause (up to 57 months)
Completed Remission (CR) Rate
CR rate: number of participants who achieved the best response of CR divided by the number of participants in the analysis population. Participants with unknown or missing response, or who provided no information on response at the end of treatment were included in the denominator when calculating rates. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent(1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods.
Time frame: From the date of randomization until the date of death from any cause (approximately 49.7 months)
CRc Rate
CRc rate was defined as participants with best response of (CR + CRp + CRi) divided by the number of participants in the analysis population. Participants were classified as: CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. CRp: achieved CR except incomplete platelet recovery (\< 100 × 10\^9/L). CRi: achieved CR except incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence not required. Percentage of participants with CRc was reported.
Time frame: From the date of randomization until the date of death from any cause (approximately 54.5 months)
Complete Remission With Partial Hematologic Recovery (CRh)
CRh was defined as the response at a post baseline visit as CRh having bone marrow myeloblast count \< 5%, partial hematologic recovery ANC ≥ 0.5 x 10\^9/L and platelets ≥ 50 x 10\^9/L, no evidence of extramedullary leukemia and cannot be classified as CR. The blast counts in peripheral blood must be ≤ 2% or missing. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. Percentage of participants with CRh was reported.
Time frame: From the date of randomization until the date of death from any cause (up to 49.7 months)
CR/CRh Rate
CR/CRh rate: number of participants who achieved CR or CRh divided by the number of participants in the analysis population. CR/CRh: CR/CRh if it fulfilled criteria for CR or CRh at the visit. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. CRh: response at a post baseline visit as CRh having bone marrow myeloblast count \< 5%, partial hematologic recovery ANC ≥ 0.5 x 10\^9/L and platelets ≥ 50 x 10\^9/L, no evidence of extramedullary leukemia and cannot be classified as CR. The blast counts in peripheral blood must be ≤ 2% or missing. Percentage of participants with CR/CRh was reported.
Time frame: From the date of randomization until the date of death from any cause (up to 49.7 months)
Percentage of Participants With Transfusion Conversion Rate
Transfusion conversion rate was defined as the number of participants who were transfusion dependent at baseline period but became transfusion independent at post-baseline period divided by the total number of participants who were transfusion dependent at baseline period.
Time frame: From baseline up to 57 months
Percentage of Participants With Transfusion Maintenance Rate
Transfusion maintenance rate was defined as the number of participants who were transfusion independent at baseline period and remained transfusion independent post-baseline period divided by the total number of participants who were transfusion independent at baseline period.
Time frame: From baseline up to 57 months
Leukemia-free Survival (LFS)
LFS: time from the date of first CRc (CR + CRp + CRi) until the date of documented relapse (excluding relapse from PR) or death for participants who achieved CRc. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. CRp: achieved CR except incomplete platelet recovery (\< 100 × 10\^9/L). CRi: achieved CR except incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence not required. CRc: fulfilled criteria for CR, CRp or CRi. Based on KM estimates.
Time frame: From first day of achieving first CRc to the first day of confirmed relapse/death (up to 54.5 months)
Duration of Remission
Duration of remission included CRc, CR, CRh, CR/CRh, and response duration \[CRc + PR\]. Duration of CRc, CR, CRh: the time from the date of first CRc until the date of first documented relapse for participants who achieved CRc, CR, and CRh, respectively. CR/CRh: fulfilled criteria for CR or CRh at the visit. CRh: marrow blasts \<5%, ANC ≥0.5×10\^9/L, platelets ≥50×10\^9/L, not meeting CR criteria. PR: If marrow myeloblasts between \<5% and 25% and ≤2% or missing peripheral blood blast and a decrease from baseline of at least 50% in the marrow myeloblasts and no evidence of extramedullary leukemia, the response was classified as PR. If marrow myeloblasts \<5% and ≤2% or missing peripheral blood blast and no evidence of extramedullary leukemia, the response was classified as PR even with Auer rods.
Time frame: From first day of achieving first response to the first day of confirmed relapse/death (up to 56.4 months)
Change From Baseline in Brief Fatigue Inventory (BFI)
The BFI was a tool to assess fatigue severity and impact on daily function in cancer participants over 24 hours. It included 9 items. A global fatigue score was computed by averaging the scores of the 9 items measured on the numeric rating scale. Scores were calculated if ≥5 of 9 items were answered. A higher score indicates a higher degree of fatigue. The first 3 rate fatigue from 0 (no fatigue) to 10 (worst imaginable), with higher scores indicating worse outcomes. The remaining 6 assess how fatigue interferes with daily activities from 0 (no interference) to 10 (completely interferes). A global fatigue score (0-10) was the average of all items, with higher scores indicating worse fatigue. Overall BFI score is reported.
Time frame: From baseline to 31 months
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. TEAE was defined as an adverse event observed after starting administration of the study drug until 30 days from the last study treatment
Time frame: From first dose up to end of study duration (101 months)
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Scores
ECOG performance scores at each assessment time were be provided by treatment group. Negative change scores indicated an improvement and positive scores indicate a decline in performance. The grades were defined as follows: 0: Fully active, able to carry on all pre-disease performance without restriction. 1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. 2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. 3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5. Dead.
Time frame: From baseline to end of treatment (up to 57 months)
Participants with newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) not eligible for intensive induction were enrolled.
| Milestone | Safety Cohort: Gilteritinib + Azacitidine (AZA) | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|---|
| Started | 15 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 15 | 0 | 0 | 0 |
| Withdrew: Miscellaneous | 2 | 0 | 0 | 0 |
| Withdrew: Disease relapse | 5 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 |
| Withdrew: Death | 5 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Milestone | Safety Cohort: Gilteritinib + Azacitidine (AZA) | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|---|
| Started | 0 | 89 | 57 | 22 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 89 | 57 | 22 |
| Withdrew: Miscellaneous | 0 | 7 | 4 | 1 |
| Withdrew: Disease relapse | 0 | 22 | 16 | 6 |
| Withdrew: Physician decision | 0 | 3 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 14 | 7 | 4 |
| Withdrew: Lack of efficacy | 0 | 4 | 14 | 0 |
| Withdrew: Death | 0 | 25 | 13 | 4 |
| Withdrew: Adverse event | 0 | 14 | 2 | 6 |
| Milestone | Safety Cohort: Gilteritinib + Azacitidine (AZA) | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|---|
| Started | 5 | 33 | 34 | 10 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 5 | 33 | 34 | 10 |
| Withdrew: Withdrawal by subject | 0 | 3 | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 |
| Withdrew: Death | 5 | 26 | 30 | 10 |
| Withdrew: Miscellaneous | 0 | 3 | 0 | 0 |
OS was defined as the time from the date of randomization until the date of death from any cause. For a participant who was not known to have died by the end of study follow-up, OS was censored at the date of last contact. Kaplan-Meier (KM) estimates was used for analysis.
| months | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|
| Overall Survival (OS) | 9.82 (8.11 to 13.17) | 9.23 (4.34 to 12.55) | 5.24 (2.46 to 15.18) |
EFS: time from the date of randomization until the date of documented relapse from Complete Remission (CR), treatment failure(failing to achieve CR within 6 cycles of treatment) or death from any cause, whichever occurred first. CR: bone marrow(BM) regenerating normal hematopoietic cells, morphologically leukemia-free state, absolute neutrophil count (ANC) ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being red blood cell (RBC) and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. Relapse: reappearance of leukemic blasts \>2% in the peripheral blood/≥ 5% myeloblasts in the BM unattributable to any other cause/new/reappearance of extramedullary leukemia.
| months | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|
| Event-free Survival (EFS) | 0.03 (NA to NA) | 0.03 (NA to NA) | 0.03 (0.03 to 2.46) |
Best response for a participant was defined as the best measured response (in the order of CR, CR with Incomplete Platelet Recovery (CRp), CR with Incomplete Hematologic Recovery (CRi), and treatment failure) from all post-baseline visits. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. CRp: achieved CR except incomplete platelet recovery (\< 100 × 10\^9/L). CRi: achieved CR except incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence not required.
| percentage of participants | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|
| CR | 25.8 | 17.5 | 9.1 |
| CRp | 6.7 | 0 | 18.2 |
| CRi | 29.2 | 10.5 | 27.3 |
CR rate: number of participants who achieved the best response of CR divided by the number of participants in the analysis population. Participants with unknown or missing response, or who provided no information on response at the end of treatment were included in the denominator when calculating rates. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent(1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods.
| percentage of participants | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|
| Completed Remission (CR) Rate | 25.8 | 17.5 | 9.1 |
CRc rate was defined as participants with best response of (CR + CRp + CRi) divided by the number of participants in the analysis population. Participants were classified as: CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. CRp: achieved CR except incomplete platelet recovery (\< 100 × 10\^9/L). CRi: achieved CR except incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence not required. Percentage of participants with CRc was reported.
| percentage of participants | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|
| CRc Rate | 61.8 | 28.1 | 54.5 |
CRh was defined as the response at a post baseline visit as CRh having bone marrow myeloblast count \< 5%, partial hematologic recovery ANC ≥ 0.5 x 10\^9/L and platelets ≥ 50 x 10\^9/L, no evidence of extramedullary leukemia and cannot be classified as CR. The blast counts in peripheral blood must be ≤ 2% or missing. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. Percentage of participants with CRh was reported.
| percentage of participants | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|
| Complete Remission With Partial Hematologic Recovery (CRh) | 10.1 | 1.8 | 22.7 |
CR/CRh rate: number of participants who achieved CR or CRh divided by the number of participants in the analysis population. CR/CRh: CR/CRh if it fulfilled criteria for CR or CRh at the visit. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. CRh: response at a post baseline visit as CRh having bone marrow myeloblast count \< 5%, partial hematologic recovery ANC ≥ 0.5 x 10\^9/L and platelets ≥ 50 x 10\^9/L, no evidence of extramedullary leukemia and cannot be classified as CR. The blast counts in peripheral blood must be ≤ 2% or missing. Percentage of participants with CR/CRh was reported.
| percentage of participants | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|
| CR/CRh Rate | 36.0 | 19.3 | 31.8 |
Transfusion conversion rate was defined as the number of participants who were transfusion dependent at baseline period but became transfusion independent at post-baseline period divided by the total number of participants who were transfusion dependent at baseline period.
| percentage of participants | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|
| Percentage of Participants With Transfusion Conversion Rate | 35.6 (24.7 to 47.7) | 44.7 (28.6 to 61.7) | 61.1 (35.7 to 82.7) |
Transfusion maintenance rate was defined as the number of participants who were transfusion independent at baseline period and remained transfusion independent post-baseline period divided by the total number of participants who were transfusion independent at baseline period.
| percentage of participants | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|
| Percentage of Participants With Transfusion Maintenance Rate | 100.0 (29.2 to 100.0) | 50.0 (1.3 to 98.7) | 50.0 (1.3 to 98.7) |
LFS: time from the date of first CRc (CR + CRp + CRi) until the date of documented relapse (excluding relapse from PR) or death for participants who achieved CRc. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. CRp: achieved CR except incomplete platelet recovery (\< 100 × 10\^9/L). CRi: achieved CR except incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence not required. CRc: fulfilled criteria for CR, CRp or CRi. Based on KM estimates.
| months | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|
| Leukemia-free Survival (LFS) | 7.16 (6.01 to 12.52) | 8.08 (2.46 to 14.09) | 3.20 (0.89 to 6.87) |
Duration of remission included CRc, CR, CRh, CR/CRh, and response duration \[CRc + PR\]. Duration of CRc, CR, CRh: the time from the date of first CRc until the date of first documented relapse for participants who achieved CRc, CR, and CRh, respectively. CR/CRh: fulfilled criteria for CR or CRh at the visit. CRh: marrow blasts \<5%, ANC ≥0.5×10\^9/L, platelets ≥50×10\^9/L, not meeting CR criteria. PR: If marrow myeloblasts between \<5% and 25% and ≤2% or missing peripheral blood blast and a decrease from baseline of at least 50% in the marrow myeloblasts and no evidence of extramedullary leukemia, the response was classified as PR. If marrow myeloblasts \<5% and ≤2% or missing peripheral blood blast and no evidence of extramedullary leukemia, the response was classified as PR even with Auer rods.
| months | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|
| Duration of CR/CRh | 19.94 (6.93 to NA) | 8.08 (0.95 to 8.57) | 2.83 (1.87 to 5.95) |
| Duration of CR | 25.10 (7.39 to NA) | 8.25 (0.95 to NA) | NA (NA to NA) |
| Duration of CRc | 12.52 (6.77 to NA) | 8.25 (2.10 to 14.09) | 3.65 (0.89 to 7.39) |
| Duration of CRh | 6.77 (1.35 to 6.93) | 8.08 (NA to NA) | 2.83 (1.87 to 5.95) |
| Duration of response | 7.92 (3.98 to 18.40) | 7.62 (0.95 to 9.23) | 3.65 (0.95 to 6.87) |
The BFI was a tool to assess fatigue severity and impact on daily function in cancer participants over 24 hours. It included 9 items. A global fatigue score was computed by averaging the scores of the 9 items measured on the numeric rating scale. Scores were calculated if ≥5 of 9 items were answered. A higher score indicates a higher degree of fatigue. The first 3 rate fatigue from 0 (no fatigue) to 10 (worst imaginable), with higher scores indicating worse outcomes. The remaining 6 assess how fatigue interferes with daily activities from 0 (no interference) to 10 (completely interferes). A global fatigue score (0-10) was the average of all items, with higher scores indicating worse fatigue. Overall BFI score is reported.
| Scores on scale | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|
| Change From Baseline in Brief Fatigue Inventory (BFI) | 0.77 ± 3.98 | 0.87 ± 2.92 | 1.37 ± 3.49 |
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. TEAE was defined as an adverse event observed after starting administration of the study drug until 30 days from the last study treatment
| participants | Safety Cohort: Gilteritinib + AZA | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 15 | 88 | 52 | 22 |
ECOG performance scores at each assessment time were be provided by treatment group. Negative change scores indicated an improvement and positive scores indicate a decline in performance. The grades were defined as follows: 0: Fully active, able to carry on all pre-disease performance without restriction. 1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. 2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. 3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5. Dead.
| participants | Safety Cohort: Gilteritinib + AZA | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|---|
| Baseline: Grade 0 | 1 | 15 | 9 | 3 |
| Baseline: Grade 1 | 4 | 34 | 26 | 6 |
| Baseline: Grade 2 | 4 | 28 | 14 | 9 |
| Baseline: Grade 3 | 6 | 10 | 5 | 3 |
| Baseline: Grade 4 | 0 | 1 | 0 | 1 |
| Baseline: Grade 5 | 0 | 0 | 0 | 0 |
| End of Treatment (EOT): Grade 0 | 1 | 4 | 8 | 2 |
| EOT: Grade 1 | 1 | 12 | 15 | 4 |
| EOT: Grade 2 | 2 | 12 | 11 | 3 |
| EOT: Grade 3 | 1 | 7 | 1 | 1 |
| EOT: Grade 4 | 1 | 6 | 1 | 1 |
| EOT: Grade 5 | 0 | 0 | 0 | 0 |
Collected over All-cause mortality (ACM): From randomization up to end of study duration (101 months) AEs: From first dose up to end of study duration (101 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Cohort: Gilteritinib + Azacitidine (AZA) | 14/15 (93.3%) | 14/15 (93.3%) | 15/15 (100%) |
| Randomized Cohort: Gilteritinib + AZA | 70/89 (78.7%) | 81/88 (92%) | 87/88 (98.9%) |
| Randomized Cohort: AZA | 49/57 (86%) | 34/54 (63%) | 46/54 (85.2%) |
| Randomized Cohort: Gilteritinib | 22/22 (100%) | 20/22 (90.9%) | 22/22 (100%) |
| Event | Safety Cohort: Gilteritinib + Azacitidine (AZA) | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 8/15 | 28/88 | 10/54 | 4/22 |
| PneumoniaInfections and infestations | 4/15 | 19/88 | 8/54 | 5/22 |
| PyrexiaGeneral disorders | 3/15 | 12/88 | 1/54 | 5/22 |
| Septic shockInfections and infestations | 2/15 | 6/88 | 1/54 | 5/22 |
| AnaemiaBlood and lymphatic system disorders | 3/15 | 4/88 | 0/54 | 2/22 |
| Atrial fibrillationCardiac disorders | 3/15 | 7/88 | 0/54 | 1/22 |
| SepsisInfections and infestations | 2/15 | 9/88 | 5/54 | 4/22 |
| Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/15 | 6/88 | 0/54 | 3/22 |
| Acute kidney injuryRenal and urinary disorders | 2/15 | 4/88 | 1/54 | 3/22 |
| NeutropeniaBlood and lymphatic system disorders | 2/15 | 0/88 | 1/54 | 0/22 |
| Event | Safety Cohort: Gilteritinib + Azacitidine (AZA) | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 8/15 | 28/88 | 18/54 | 6/22 |
| NeutropeniaBlood and lymphatic system disorders | 7/15 | 28/88 | 16/54 | 3/22 |
| DiarrhoeaGastrointestinal disorders | 7/15 | 30/88 | 10/54 | 9/22 |
| PyrexiaGeneral disorders | 2/15 | 37/88 | 17/54 | 5/22 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/15 | 29/88 | 11/54 | 4/22 |
| NauseaGastrointestinal disorders | 6/15 | 27/88 | 13/54 | 3/22 |
| FatigueGeneral disorders | 6/15 | 8/88 | 5/54 | 0/22 |
| Alanine aminotransferase increasedInvestigations | 6/15 | 15/88 | 5/54 | 3/22 |
| Aspartate aminotransferase increasedInvestigations | 6/15 | 19/88 | 3/54 | 4/22 |
| ConstipationGastrointestinal disorders | 5/15 | 35/88 | 13/54 | 5/22 |
The Full Analysis Set (FAS) was defined as the intention to treat set, which consisted of participants who were randomized and were used for efficacy analyses.
| Age, Continuous(Years) | Safety Cohort: Gilteritinib + Azacitidine (AZA) | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib | Total |
|---|---|---|---|---|---|
| Mean | 75.3 ± 5.6 | 77.1 ± 5.7 | 76.9 ± 5.2 | 78.5 ± 4.2 | 77.1 ± 5.4 |
| Sex: Female, Male(Participants) | Safety Cohort: Gilteritinib + Azacitidine (AZA) | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib | Total |
|---|---|---|---|---|---|
| Female | 8 | 40 | 27 | 10 | 85 |
| Male | 7 | 49 | 30 | 12 | 98 |
| Ethnicity (NIH/OMB)(Participants) | Safety Cohort: Gilteritinib + Azacitidine (AZA) | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 4 | 1 | 7 |
| Not Hispanic or Latino | 14 | 75 | 46 | 18 | 153 |
| Unknown or Not Reported | 1 | 12 | 7 | 3 | 23 |
| Race/Ethnicity, Customized(Participants) | Safety Cohort: Gilteritinib + Azacitidine (AZA) | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib | Total |
|---|---|---|---|---|---|
| Race — White | 11 | 53 | 33 | 9 | 106 |
| Race — Asian | 3 | 25 | 15 | 10 | 53 |
| Race — Unknown | 1 | 11 | 8 | 2 | 22 |
| Race — Other | 0 | 0 | 1 | 1 | 2 |
| Age group per Interactive Response Technology (IRT)(Participants) | Safety Cohort: Gilteritinib + Azacitidine (AZA) | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib | Total |
|---|---|---|---|---|---|
| < 75 years | 6 | 27 | 15 | 4 | 52 |
| >= 75 years | 9 | 62 | 42 | 18 | 131 |
| FMS-like tyrosine kinase 3 (FLT3) mutation type(Participants) | Safety Cohort: Gilteritinib + Azacitidine (AZA) | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib | Total |
|---|---|---|---|---|---|
| Internal Tandem Duplication (ITD) Alone | 10 | 70 | 46 | 17 | 143 |
| Tyrosine Kinase Domain (TKD) (D835/I836) Alone | 3 | 16 | 9 | 2 | 30 |
| ITD with TKD (D835/I836) | 1 | 3 | 2 | 3 | 9 |
| Others (unknown/missing/negative) | 1 | 0 | 0 | 0 | 1 |
| Cytogenetic risk status(Participants) | Safety Cohort: Gilteritinib + Azacitidine (AZA) | Randomized Cohort: Gilteritinib + AZA | Randomized Cohort: AZA | Randomized Cohort: Gilteritinib | Total |
|---|---|---|---|---|---|
| Favorable | 0 | 2 | 0 | 0 | 2 |
| Intermediate | 11 | 63 | 40 | 17 | 131 |
| Unfavorable | 1 | 9 | 6 | 0 | 16 |
| Others (unknown, missing) | 3 | 15 | 11 | 5 | 34 |
Showing the first 100 of 111 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Data sharing details ↗ · www.clinicaltrials.astellas.com
Ran from Aug 2016 to primary completion in Mar 2023, 79 months.
Results were first posted in Sep 2025, 2 years 6 months after primary completion. A results delay was requested in Mar 2024.
Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 79 months is above that.
Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gilteritinib · Azacitidine
Astellas Pharma Global Development, Inc. →